Longevity Health Stock (NASDAQ:XAGE)

Revenue Financials Chart

Previous Close

$3.88

52W Range

$2.20 - $38.10

50D Avg

$3.09

200D Avg

$7.13

Market Cap

$5.80M

Avg Vol (3M)

$2.27M

Beta

0.49

Div Yield

XAGE Company Profile

Longevity Health Holdings Inc focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Sep 23, 2021

Website

XAGE Performance

XAGE Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-5.22M	$-5.51M	$-1.94M
Net Income	$-15.45M	$-9.05M	$-6.48M
EBITDA	$-15.19M	$-5.25M	$-1.66M
Basic EPS	$-1.46	$-0.46	$-0.33
Diluted EPS	$-1.46	$-0.46	$-0.33

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
PHH	Park Ha Biological Technology Co., Ltd.
PHH	Park Ha Biological Technology Co., Ltd.
HIMS	Hims & Hers Health, Inc.
ARBB	ARB IOT Group Limited
BGLC	BioNexus Gene Lab Corp.
EL	The Estée Lauder Companies Inc.
CLX	The Clorox Company
NITO	N2OFF, Inc.
NWL	Newell Brands Inc.
HNST	The Honest Company, Inc.